Skip to main content
Top
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 12/2019

Open Access 01-12-2019 | Diabetic Retinopathy | Retinal Disorders

Natural history of diabetic macular edema and factors predicting outcomes in sham-treated patients (MEAD study)

Authors: Young Hee Yoon, David S. Boyer, Raj K. Maturi, Francesco Bandello, Rubens Belfort Jr, Albert J. Augustin, Xiao-Yan Li, Zhanying Bai, Yehia Hashad, on behalf of the Ozurdex MEAD Study Group

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 12/2019

Login to get access

Abstract

Purpose

To describe the natural history of diabetic macular edema (DME) with respect to best-corrected visual acuity (BCVA) and central retinal thickness (CRT) outcomes and to identify baseline patient characteristics and systemic factors associated with improvement or worsening of outcomes in sham-treated patients.

Methods

The study population was sham-treated patients (n = 350) in the 3-year MEAD registration study of dexamethasone intravitreal implant for treatment of DME. Patients had center-involved DME and received sham intravitreal injections in the study eye at ≥ 6-month intervals. Potential prognostic factors for outcomes were evaluated using multiple linear regression analysis.

Results

Visual and anatomic outcomes were poorer in patients who left the study early (n = 198) than in study completers (n = 152). Mean change in BCVA from baseline at the last visit with available data was + 0.9 letters; 37.5% of patients had no change in BCVA, 23.2% had gained > 10 letters, and 16.0% had lost > 10 letters. Older age and baseline diabetic retinopathy score > 6 were associated with worse BCVA outcomes; thicker baseline CRT and larger number of hypertension medications used were associated with larger reductions in CRT during the study.

Conclusions

BCVA and CRT outcomes were variable in this population of DME patients with generally good glycemic control. In DME patients without active treatment, older age and baseline diabetic retinopathy score > 6 were associated with less improvement in BCVA; thicker baseline CRT and a larger number of antihypertensive medications used predicted better improvement in CRT.

Trial registration

The MEAD study trials are registered at ClinicalTrials.​gov with the identifiers NCT00168337 and NCT00168389.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wong TY, Sun J, Kawasaki R et al (2018) Guidelines on diabetic eye care: the International Council of Ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology 125:1608–1622CrossRef Wong TY, Sun J, Kawasaki R et al (2018) Guidelines on diabetic eye care: the International Council of Ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology 125:1608–1622CrossRef
2.
go back to reference Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R (2016) Diabetic macular edema pathophysiology: vasogenic versus inflammatory. J Diabetes Res 2016:2156273CrossRef Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R (2016) Diabetic macular edema pathophysiology: vasogenic versus inflammatory. J Diabetes Res 2016:2156273CrossRef
3.
go back to reference Ou WC, Brown DM, Payne JF, Wykoff CC (2017) Relationship between visual acuity and retinal thickness during anti-vascular endothelial growth factor therapy for retinal diseases. Am J Ophthalmol 180:8–17CrossRef Ou WC, Brown DM, Payne JF, Wykoff CC (2017) Relationship between visual acuity and retinal thickness during anti-vascular endothelial growth factor therapy for retinal diseases. Am J Ophthalmol 180:8–17CrossRef
4.
go back to reference Yau JW, Rogers SL, Kawasaki R et al (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35:556–564CrossRef Yau JW, Rogers SL, Kawasaki R et al (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35:556–564CrossRef
5.
go back to reference Miljanovic B, Glynn RJ, Nathan DM, Manson JE, Schaumberg DA (2004) A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes 53:2883–2892CrossRef Miljanovic B, Glynn RJ, Nathan DM, Manson JE, Schaumberg DA (2004) A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes 53:2883–2892CrossRef
6.
go back to reference Kawasaki R, Konta T, Nishida K (2018) Lipid-lowering medication use is associated with decreased risk of diabetic retinopathy and its treatments in patients with type 2 diabetes: a real-world observational analysis of a health claims database. Diabetes Obes Metab 20:2351–2360CrossRef Kawasaki R, Konta T, Nishida K (2018) Lipid-lowering medication use is associated with decreased risk of diabetic retinopathy and its treatments in patients with type 2 diabetes: a real-world observational analysis of a health claims database. Diabetes Obes Metab 20:2351–2360CrossRef
7.
go back to reference Diep TM, Tsui I (2013) Risk factors associated with diabetic macular edema. Diabetes Res Clin Pract 100:298–305CrossRef Diep TM, Tsui I (2013) Risk factors associated with diabetic macular edema. Diabetes Res Clin Pract 100:298–305CrossRef
8.
go back to reference Perkovich BT, Meyers SM (1988) Systemic factors affecting diabetic macular edema. Am J Ophthalmol 105:211–212CrossRef Perkovich BT, Meyers SM (1988) Systemic factors affecting diabetic macular edema. Am J Ophthalmol 105:211–212CrossRef
9.
go back to reference Zhang X, Yang J, Zhong Y et al (2017) Association of bone metabolic markers with diabetic retinopathy and diabetic macular edema in elderly Chinese individuals with type 2 diabetes mellitus. Am J Med Sci 354:355–361CrossRef Zhang X, Yang J, Zhong Y et al (2017) Association of bone metabolic markers with diabetic retinopathy and diabetic macular edema in elderly Chinese individuals with type 2 diabetes mellitus. Am J Med Sci 354:355–361CrossRef
10.
go back to reference Ryan EH Jr, Han DP, Ramsay RC, Cantrill HL, Bennett SR, Dev S, Williams DF (2006) Diabetic macular edema associated with glitazone use. Retina 26:562–570CrossRef Ryan EH Jr, Han DP, Ramsay RC, Cantrill HL, Bennett SR, Dev S, Williams DF (2006) Diabetic macular edema associated with glitazone use. Retina 26:562–570CrossRef
11.
go back to reference Fong DS, Contreras R (2009) Glitazone use associated with diabetic macular edema. Am J Ophthalmol 147:583–586.e1CrossRef Fong DS, Contreras R (2009) Glitazone use associated with diabetic macular edema. Am J Ophthalmol 147:583–586.e1CrossRef
12.
go back to reference Macky TA, Mahgoub MM (2013) The effect of glycemic control on visual and anatomic outcomes in response to therapy for diabetic macular edema. Eur J Ophthalmol 23:94–100CrossRef Macky TA, Mahgoub MM (2013) The effect of glycemic control on visual and anatomic outcomes in response to therapy for diabetic macular edema. Eur J Ophthalmol 23:94–100CrossRef
13.
go back to reference Yamada Y, Suzuma K, Ryu M, Tsuiki E, Fujikawa A, Kitaoka T (2013) Systemic factors influence the prognosis of diabetic macular edema after pars plana vitrectomy with internal limiting membrane peeling. Curr Eye Res 38:1261–1265CrossRef Yamada Y, Suzuma K, Ryu M, Tsuiki E, Fujikawa A, Kitaoka T (2013) Systemic factors influence the prognosis of diabetic macular edema after pars plana vitrectomy with internal limiting membrane peeling. Curr Eye Res 38:1261–1265CrossRef
14.
go back to reference Matsuda S, Tam T, Singh RP, Kaiser PK, Petkovsek D, Carneiro G, Zanella MT, Ehlers JP (2014) The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema. J Diabetes Complicat 28:166–170CrossRef Matsuda S, Tam T, Singh RP, Kaiser PK, Petkovsek D, Carneiro G, Zanella MT, Ehlers JP (2014) The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema. J Diabetes Complicat 28:166–170CrossRef
15.
go back to reference Singh RP, Habbu K, Ehlers JP, Lansang MC, Hill L, Stoilov I (2016) The impact of systemic factors on clinical response to ranibizumab for diabetic macular edema. Ophthalmology 123:1581–1587CrossRef Singh RP, Habbu K, Ehlers JP, Lansang MC, Hill L, Stoilov I (2016) The impact of systemic factors on clinical response to ranibizumab for diabetic macular edema. Ophthalmology 123:1581–1587CrossRef
16.
go back to reference Nguyen QD, Brown DM, Marcus DM et al (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119:789–801CrossRef Nguyen QD, Brown DM, Marcus DM et al (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119:789–801CrossRef
17.
go back to reference Bansal AS, Khurana RN, Wieland MR, Wang PW, Van Everen SA, Tuomi L (2015) Influence of glycosylated hemoglobin on the efficacy of ranibizumab for diabetic macular edema: a post hoc analysis of the RIDE/RISE trials. Ophthalmology 122:1573–1579CrossRef Bansal AS, Khurana RN, Wieland MR, Wang PW, Van Everen SA, Tuomi L (2015) Influence of glycosylated hemoglobin on the efficacy of ranibizumab for diabetic macular edema: a post hoc analysis of the RIDE/RISE trials. Ophthalmology 122:1573–1579CrossRef
18.
go back to reference American Diabetes Association (2014) Standards of medical care in diabetes—2014. Diabetes Care 37(Suppl 1):S14–S80CrossRef American Diabetes Association (2014) Standards of medical care in diabetes—2014. Diabetes Care 37(Suppl 1):S14–S80CrossRef
19.
go back to reference Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM, Ozurdex MEAD Study Group (2014) Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121:1904–1914CrossRef Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM, Ozurdex MEAD Study Group (2014) Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121:1904–1914CrossRef
20.
go back to reference Augustin AJ, Kuppermann BD, Lanzetta P, Loewenstein A, Li XY, Cui H, Hashad Y, Whitcup SM, Ozurdex MEAD Study Group (2015) Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmol 15:150CrossRef Augustin AJ, Kuppermann BD, Lanzetta P, Loewenstein A, Li XY, Cui H, Hashad Y, Whitcup SM, Ozurdex MEAD Study Group (2015) Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmol 15:150CrossRef
21.
go back to reference Danis RP, Sadda S, Li XY, Cui H, Hashad Y, Whitcup SM (2016) Anatomical effects of dexamethasone intravitreal implant in diabetic macular oedema: a pooled analysis of 3-year phase III trials. Br J Ophthalmol 100:796–801CrossRef Danis RP, Sadda S, Li XY, Cui H, Hashad Y, Whitcup SM (2016) Anatomical effects of dexamethasone intravitreal implant in diabetic macular oedema: a pooled analysis of 3-year phase III trials. Br J Ophthalmol 100:796–801CrossRef
22.
go back to reference Maturi RK, Pollack A, Uy HS, Varano M, Gomes AM, Li XY, Cui H, Lou J, Hashad Y, Whitcup SM, Ozurdex MEAD Study Group (2016) Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina 36:1143–1152CrossRef Maturi RK, Pollack A, Uy HS, Varano M, Gomes AM, Li XY, Cui H, Lou J, Hashad Y, Whitcup SM, Ozurdex MEAD Study Group (2016) Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina 36:1143–1152CrossRef
23.
go back to reference Early Treatment Diabetic Retinopathy Study Research Group (1991) Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 98(5 Suppl):823–833 Early Treatment Diabetic Retinopathy Study Research Group (1991) Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 98(5 Suppl):823–833
24.
go back to reference Brown DM, Nguyen QD, Marcus DM et al (2013) Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120:2013–2022CrossRef Brown DM, Nguyen QD, Marcus DM et al (2013) Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120:2013–2022CrossRef
25.
go back to reference Gower EW, Lovato JF, Ambrosius WT, Chew EY, Danis RP, Davis MD, Goff DC Jr, Greven CM, ACCORD Study Group (2018) Lack of longitudinal association between thiazolidinediones and incidence and progression of diabetic eye disease: the ACCORD Eye Study. Am J Ophthalmol 187:138–147CrossRef Gower EW, Lovato JF, Ambrosius WT, Chew EY, Danis RP, Davis MD, Goff DC Jr, Greven CM, ACCORD Study Group (2018) Lack of longitudinal association between thiazolidinediones and incidence and progression of diabetic eye disease: the ACCORD Eye Study. Am J Ophthalmol 187:138–147CrossRef
27.
go back to reference Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN (2015) Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev (1):CD006127 Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN (2015) Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev (1):CD006127
28.
go back to reference Shi R, Zhao L, Wang F, Liu F, Chen Z, Li R, Liu Y, Lin R (2018) Effects of lipid-lowering agents on diabetic retinopathy: a meta-analysis and systematic review. Int J Ophthalmol 11:287–295PubMedPubMedCentral Shi R, Zhao L, Wang F, Liu F, Chen Z, Li R, Liu Y, Lin R (2018) Effects of lipid-lowering agents on diabetic retinopathy: a meta-analysis and systematic review. Int J Ophthalmol 11:287–295PubMedPubMedCentral
29.
go back to reference Khan HA, Sobki SH, Khan SA (2007) Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. Clin Exp Med 7:24–29CrossRef Khan HA, Sobki SH, Khan SA (2007) Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. Clin Exp Med 7:24–29CrossRef
30.
go back to reference Sophie R, Lu N, Campochiaro PA (2015) Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab. Ophthalmology 122:1395–1401CrossRef Sophie R, Lu N, Campochiaro PA (2015) Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab. Ophthalmology 122:1395–1401CrossRef
31.
go back to reference Ajoy Mohan VK, Nithyanandam S, Idiculla J (2011) Microalbuminuria and low hemoglobin as risk factors for the occurrence and increasing severity of diabetic retinopathy. Indian J Ophthalmol 59:207–210CrossRef Ajoy Mohan VK, Nithyanandam S, Idiculla J (2011) Microalbuminuria and low hemoglobin as risk factors for the occurrence and increasing severity of diabetic retinopathy. Indian J Ophthalmol 59:207–210CrossRef
Metadata
Title
Natural history of diabetic macular edema and factors predicting outcomes in sham-treated patients (MEAD study)
Authors
Young Hee Yoon
David S. Boyer
Raj K. Maturi
Francesco Bandello
Rubens Belfort Jr
Albert J. Augustin
Xiao-Yan Li
Zhanying Bai
Yehia Hashad
on behalf of the Ozurdex MEAD Study Group
Publication date
01-12-2019
Publisher
Springer Berlin Heidelberg
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 12/2019
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-019-04464-2

Other articles of this Issue 12/2019

Graefe's Archive for Clinical and Experimental Ophthalmology 12/2019 Go to the issue